Immunotherapy for autoimmune and inflammatory renal diseases

Current Opinion in Nephrology and Hypertension

Volumn 7, Issue 3, 1998, Pages 311-315

  Jayne, David R W ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; AUTOANTIBODY; AUTOANTIGEN; B7 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CHEMOKINE; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; CREATININE; CYTOKINE; CYTOKINE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA; DNA ANTIBODY; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE;

ALLERGIC REACTION; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL TRIAL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE DEPLETION; NEPHRITIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0031809775     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199805000-00012     Document Type: Article

References (46)

1. Norrby-Teglund A, Kaul R, Low DE, McGeer A, Andersson J, Andersson U, Kotb M. Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect Immun 1996; 64:5395-5398.
2. Brooks CJ, King WJ, Radford DJ, Adu D, McGrath M, Savage COS. IL-1 beta production by human polymorphonuclear leucocytes stimulated by anti-neutrophil cytoplasm autoantibodies. Clin Exp Immunol 1996; 106:273-279.
3. +)2 fragments (5S IVIg) and Fc fragments. Evidence for post-transcriptional IL-2 modulation. Immunology 1997; 90:212-218.
4. Toungouz M, Denys C, Dupont E. Blockade of proliferation and tumor necrosis factor-alpha production occurring during mixed lymphocyte reaction by interferon-gamma-specific natural antibodies contained in intravenous immunoglobulins. Transplantation 1996; 62:1292-1296.
5. Andersson J, Skansen-Saphir U, Sparrelid E, Andersson U. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 1996; 104 (Suppl 1):10-20.
6. Jayne DRW, Lockwood CM. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Q J Med 1996; 35:1150-1153.
7. Lockwood CM. New treatment strategies for systemic vasculitis: the role of intravenous immunoglobulin therapy. Clin Exp Immunol 1996; 104 (Suppl 1):77-82.
8. Jayne DRW, Rasmussen N, for the European Community Systemic Vasculitis Study Group (ECSYSVASTRIAL). Treatment ot antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Study Group. Mayo Clin Proc 1997; 72:737-748.
9. Schroeder JO, Zeuner RA, Euler HH, Loffler H. High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 1996; 23:71-75.
10. Puddu P, De Pieta O, Ruffelli M, Bellucci AM, Giradelli CR, Galeazzi M, Marcolongo R. Intravenous immunoglobulin therapy: modification of the immunofluorescence pattern in the skin of six patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39:704-705.
11. Silvestris F, Damore O, Cafforio P, Savino L, Damacco F. Intravenous immune globulin therapy of lupus nephritis: use of pathogenic anti-DNA-reactive IgG. Clin Exp Immunol 1996; 104 (Suppl 1):91-97. Immunoglobulin, selected for reactivity with anti-DNA antibodies, was compared with untreated immunoglobulin in lupus nephritis.
12. Lafferty TE, Smith JB, Schuster SJ, Dehoratius RJ. Treatment of acquired factor VIII inhibitor using intravenous immunoglobulin in two patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40:775-778.
13. Lesprit P, Mouloud F, Bierling P, Schaeffer A, Cesaro P, Brun-Buisson C, Godeau B. Prolonged remission of SLE-associated polyradiculopathy after a single course of intravenous immunoglobulin. Scan J Rheumatol 1996; 25:177-179.
14. Blanco R, Gonzalez-Gay MA, Ibanez D, Sanchez-Andrade A, Gonzalez-Vela C. Paradoxical and persistent renal impairment in Henoch-Schönlein purpura after high-dose immunoglobulin therapy. Nephron 1997; 76:247-248.
15. Hansen-Schmidt S, Silomon J, Keller F. Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis. Am J Kidney Dis 1996; 28:451-453.
16. Jarvis LM, Davidson F, Hanley JP, Yap PL, Ludlam CA, Simmonds P. Infection with hepatitis G virus among recipients of plasma products. Lancet 1996; 348:1352-1355.
17. Hashkes PJ, Lovell DJ. Vasculitis in systemic lupus erythematosus following intravenous immunoglobulin therapy. Clin Exp Rheumatol 1996; 14:673-675.
18. Lockwood CM, Thiru S, Stewart S, Hale G, Isaacs J, Wraight P, et al. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. Q J Med 1996; 89:903-912. The combination of two humanized monoclonal antibodies induced lymphocyte depletion and sustained clinical remission.
19. Isaacs JD, Manna VK, Rapson N, Bulpitt KJ, Hazleman BL, Matteson EL, et al. CAMPATH-1H in rheumatoid arthritis: an intravenous dose ranging study. Br J Rheumatol 1996; 35:231-240.
20. Schnitzer TJ, Yocum DE, Michalska M, Balius R, Snider ME, Hays A, et al. Subcutaneous administration of CAMPATH-1H: clinical and biological outcomes. J Rheumatol 1997; 24:1031-1036.
21. Prinz JC, Meurer M, Reiter C, Rieber EP, Plewig G, Riethmuller G. Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, CM-T412. J Am Acad Dermatol 1996; 34:244-252.
22. Griffith ME, Coulthart A, Pusey CD. T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis. Clin Exp Immunol 1996; 103:253-258.
23. Waisman A, Ruiz PJ, Israeli E, Eilat E, Konen-Waisman S, Zinger H, et al. Modulation of murine systemic lupus erythematosus with peptide based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. Proc Natl Acad Sci USA 1997; 94:4620-4625. Peptides derived from a monoclonal anti-DNA antibody, which bound to major histocompatibility class II molecules, could both induce neonatal tolerance and inhibit anti-DNA antibody specific lymphocyte proliferation.
24. Datta SK, Kaliyaperumal A, Desai-Mehta A. T cells of lupus and molecular targets for immunotherapy. J Clin Immunol 1997; 17:11-20.
25. Pham K, Smoyer WE, Archer DC, Gabbai F, Kelly CJ. Oral feeding of renal tubular antigen abrogates interstitial nephritis and renal failure in Brown Norway rats. Kidney Int 1997; 52:725-732.
26. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996; 97:2063-2073. Increased expression of CD40 ligand in T and B cells from active lupus patients was demonstrated. A monoclonal antibody to CD40 ligand reduced autoantibody production from lupus lymphocytes in vitro.
27. Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997; 159:3104-3108.
28. Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 1996; 157:3159-3164. A monoclonal antibody to CD40 ligand reduced severe nephritis and increased survival by 50% in a murine lupus model.
29. Yellin MJ, D'Agati V, Parkinson G, Soh-Yung Han S, Szema A, Baum D, et al. Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritides and other glomerulonephritides. Arthritis Rheum 1997; 40:121-134.
30. Chapman PT, Griffin SV, Moguilevsky N, Elliott J, Lockwood CM. The use of a recombinant myeloperoxidase (rec-MPO) column to selectively remove anti-MPO antibodies from human sera: preclinical feasibility studies [abstract]. Sarcoidosis 1996; 13:276.
31. Audrain MA, Baranger TA, Moguilevski N, Devys A, Lockwood CM, Muller JY, Esnault VLM. Anti-native and recombinant myeloperoxidase monoclonals and autoantibodies. Clin Exp Immunol 1997; 107:127-134.
32. DeKeyser F, DeKeyser H, Kazatchkine MD, Rossi F, Dang H, Talal N. Pooled human immunoglobulins contain anti-idiotypes with reactivity against the SLE-associated 4B4 cross-reactive idiotype. Clin Exp Rheum 1996; 14:587-591.
33. Strunz HP, Csernok E, Gross WL. Incidence and disease associations of a proteinase 3-antineutrophil cytoplasmic antibody idiotype (5/7 Id) whose antiidiotype inhibits proteinase 3-anti-neutrophil cytoplasmic antibody activity. Arthritis Rheum 1997; 40:135-142.
34. Williams RCJ, Malone CG, Fry G, Silvestris F. Affinity columns containing anti-DNA Id + human myeloma proteins adsorb human epibodies from intravenous gamma globulin. Arthritis Rheum 1997; 40:683-693.
35. Burny W, Lebrun P, Cosyns JP, Saintremy JMR. Treatment with dsDNA-anti-dsDNA antibody complexes extends survival, decreases anti-dsDNA antibody production and reduces severity of nephritis in MRLlpr mice. Lupus 1997; 6:4-17.
36. Tipping PG, Kitching AR, Huang XR, Mutch DA, Holdsworth SR. Immune modulation with interleukin-4 and interleukin-10 prevents crescent formation and glomerular injury in experimental glomerulonephritis. Eur J Immunol 1997; 27:530-537.
37. Huang XR, Tipping PG, Shuo L, Holdsworth SR. Th1 responsiveness to nephritogenic amines determines susceptibility to crescentic glomerulonephritis in mice. Kidney Int 1997; 51:94-103.
38. Lan HY, Bacher M, Yang N, Mu W, Mikolic-Paterson DJ, Metx C. et al. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat. J Exp Med 1997; 185:1455-1465.
39. Nikolic-Paterson DJ, Lan HY, Atkins RC. Interleukin-1 receptor antagonism. Semin Nephrol 1996; 16:583-590.
40. Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci U S A 1996; 93:8563-8568.
41. Savage COS. The interaction of endothelial cells with inflammatory cells in vasculitis. Sarcoidosis 1996; 13:214-216.
42. Kootstra CJ, van der Giezen DM, van Krieken JHJM, de Heer E, Bruijn JA. Effective treatment of experimental lupus nephritis by combined administration of anti-CD11a and anti-CD54 antibodies. Clin Exp Immunol 1997; 108:324-332.
43. Drummond C, Lockwood CM, Merrill C, Hazleman B, Wraight P, Peat D, et al. Intervention in clinical refractory systemic vasculitis by humanised monoclonal antibodies against adhesion molecules [abstract]. Sarcoidosis 1996; 13:277.
44. Wicks I, Cooley H, Szer J. Autologous stem cell transplantation: a possible cure for rheumatoid arthritis? Arthritis Rheum 1997; 40:1005-1011.
45. Passweg JR, Fassas A, Black CM, Finke J, Jouet JP, Locatelli F, et al. Autologous stem cell transplantation for autoimmune disease. A preliminary report. (For the EBMT/EULAR autoimmune disease stem cell project; Basle, Switzerland) [abstract]. Blood 1997; 90 (Suppl 1):2338
46. Durand-Zaleski I, Bastuji-Garin S, Zaleski S, Weil B, Rostoker G. A cost analysis of the prevention of end-stage renal disease: immunoglobulin therapy for IgA nephropathy. Med Decis Making 1996; 16:326-334.